Keyphrases
5-fluorouracil (5-FU)
15%
Adverse Events
14%
Androgen Deprivation Therapy
9%
Anthracyclines
12%
Breast Cancer
16%
Cancer Cachexia
11%
Cancer Treatment
84%
Carboplatin
22%
Carboplatin-paclitaxel
10%
Cetuximab
10%
Chemotherapy
15%
Cisplatin
19%
Clinical Trials
10%
Combined Modality Therapy
10%
Complete Response
9%
Confidence Interval
28%
Diarrhea
9%
Eastern Cooperative Oncology Group
9%
Gemcitabine
20%
Group Studies
18%
Hot Flashes
15%
Irinotecan
12%
Leucovorin
13%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
26%
Median Survival
11%
Median Time
11%
Megestrol Acetate
10%
Metastatic Breast Cancer
24%
NCCTG
31%
Neutropenia
10%
Non-small Cell Lung Cancer (NSCLC)
19%
North Central
80%
Overall Survival
13%
Oxaliplatin
16%
Paclitaxel
13%
Partial Response
15%
Pemetrexed
12%
Performance Status
9%
Phase II Study
47%
Phase II Trial
67%
Placebo
43%
Previously Treated
9%
Progression-free Survival
14%
Quality of Life
14%
Radiation Therapy
9%
Randomized Placebo-controlled Trial
18%
Rash
12%
Response Rate
18%
Taxanes
14%
Treatment Group
80%
Pharmacology, Toxicology and Pharmaceutical Science
Adenocarcinoma
7%
Advanced Cancer
6%
Adverse Event
20%
Androgen
15%
Anorexia
11%
Anthracycline
12%
Aromatase Inhibitor
6%
Breast Cancer
18%
Carboplatin
27%
Cetuximab
10%
Chemotherapy
26%
Cisplatin
22%
Clinical Trial
17%
Dexamethasone
6%
Diarrhea
8%
Disease
18%
Disease Exacerbation
8%
Docetaxel
7%
Doxorubicin
8%
Dyspnea
7%
Epidermal Growth Factor Receptor Kinase Inhibitor
6%
Etoposide
8%
Fluorouracil
14%
Folinic Acid
10%
Gemcitabine
21%
Group Trial
11%
Hot Flush
13%
Irinotecan
12%
Malignant Neoplasm
100%
Megestrol Acetate
10%
Melanoma
10%
Metastatic Breast Cancer
26%
Neoplasm
17%
Neutropenia
10%
Non Small Cell Lung Cancer
40%
Overall Survival
20%
Oxaliplatin
13%
Paclitaxel
19%
Pancreas Adenocarcinoma
7%
Pemetrexed
13%
Phase II Trials
54%
Placebo
59%
Progression Free Survival
23%
Prostate Cancer
13%
Rash
10%
Recombinant Erythropoietin
7%
Small Cell Lung Cancer
10%
Survival Rate
6%
Symptom
7%
Taxane
14%
Medicine and Dentistry
Adverse Event
10%
Androgen
8%
Anorexia
6%
Arm
16%
Breast Cancer
24%
Bupropion
5%
Cancer Therapy
40%
Capecitabine
5%
Carboplatin
8%
Cetuximab
5%
Cisplatin
14%
Clinical Trial
8%
Continuous Infusion
5%
Diarrhea
5%
Disease
10%
Doxorubicin
5%
Exemestane
5%
Fluorouracil
5%
Gefitinib
5%
Gemcitabine
7%
Group Trial
8%
Hot Flush
5%
Low Drug Dose
5%
Lymph Node
7%
Malignant Neoplasm
19%
Metastatic Breast Cancer
7%
Metastatic Carcinoma
7%
Multimodality Cancer Therapy
5%
Neck
5%
Neoplasm
12%
Nodular Melanoma
5%
Non Small Cell Lung Cancer
24%
Oncology
13%
Optical Coherence Tomography
8%
Overall Survival
9%
Oxaliplatin
7%
Paclitaxel
6%
Phase II Trials
19%
Placebo
40%
Prognostic Factor
5%
Progression Free Survival
7%
Prostate Cancer
10%
Quality of Life
10%
Radiation Therapy
8%
Randomized Controlled Trial
7%
Survival Rate
5%
Symptom
6%
Temsirolimus
5%
Topotecan
5%